ImmuVen awarded $1.68M NIH Phase II SBIR grant to develop IMV0123

ImmuVen (www.immuven.com) was awarded a Phase II Small Business Innovation Research (SBIR) grant totaling $1.68 million from the National Institute for Allergy and Infectious Disease (NIH) for continuing development of its therapeutic pipeline (IMV0123) against superantigens produced by methicillin-sensitive and methicillin-resistant Staphylococcal aureus. This award continues the work previously supported by a successfully completed Phase I SBIR grant.

ImmuVen's biotherapeutic approach to neutralizing superantigen toxicity is uniquely positioned to intervene in deaths and morbidity caused by superantigen production in a host of S. aureus infections including pneumonia and endocarditis. The goal of this award is to provide support for bringing IMV0123 through a pre-Investigational New Drug (IND) meeting with the Food and Drug Administration (FDA) in addition to completing major milestones in the preclinical development of the therapeutic.